Alnylam Pharmaceuticals (ALNY) Income towards Parent Company (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Income towards Parent Company for 18 consecutive years, with $164.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income towards Parent Company rose 327.74% year-over-year to $164.5 million; the trailing twelve-month figure through Jun 2026 stood at $774.7 million (up 371.06% YoY), and the FY2025 full-year result was $313.7 million, up 212.79% from the prior year.
• Income towards Parent Company slipped to $164.5 million in Q2 2026 per ALNY's latest filing, from $206.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $292.7 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
• Historically, Income towards Parent Company has averaged -$64.7 million across 5 years, with a median of -$78.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Income towards Parent Company slumped 327.66% in 2025, then jumped 1228.66% in 2026.
• Over 5 years, Income towards Parent Company stood at -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then soared by 233.17% to $111.5 million in 2025, then jumped by 47.47% to $164.5 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $164.5 million, $206.0 million, and $111.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.